Impact of clinical variables and T-cell repertoire metrics on RFS at 3 years
| No recurrence (n=20) | Recurrence (n=29) | P value | |
| Sex | |||
| Female | 9 (45.0%) | 9 (31.0%) | 0.995 |
| Male | 11 (55.0%) | 20 (69.0%) | |
| Age | |||
| Mean (SD) | 73.4 (12.1) | 68.4 (7.91) | 0.632 |
| Median (min, max) | 75.0 (50.0, 89.0) | 69.0 (54.0, 83.0) | |
| Grade 2 | |||
| High | 5 (25.0%) | 10 (34.5%) | NA |
| Low/intermediate | 15 (75.0%) | 19 (65.5%) | |
| P value | 0 (0%) | 0 (0%) | |
| T cell infiltrates | |||
| High | 7 (35.0%) | 4 (13.8%) | 0.13 |
| Low | 2 (10.0%) | 8 (27.6%) | |
| Moderate | 11 (55.0%) | 17 (58.6%) | |
| Clonality | |||
| High | 9 (45.0%) | 12 (41.4%) | 0.194 |
| Moderate/low | 11 (55.0%) | 17 (58.6%) | |
| T cells total | |||
| Mean (SD) | 0.165 (0.146) | 0.170 (0.134) | 0.289 |
| Median (min, max) | 0.105 (0.0100, 0.620) | 0.140 (0.0200, 0.670) | |
| Overall survival | |||
| Mean (SD) | 4.68 (4.60) | 3.34 (3.18) | 0.98 |
| Median (min, max) | 2.60 (0.300, 17.4) | 2.00 (0.400, 13.8) | |
| Total immune content | |||
| Mean (SD) | 0.365 (0.225) | 0.372 (0.218) | 0.678 |
| Median (min, max) | 0.305 (0.100, 0.960) | 0.320 (0.0700, 0.900) |
A t-test was used for continuous data, and a χ2 test was used for categorical data to analyze clinical characteristics and immunosequencing data in relation to RFS at 3 years.
RFS, recurrence-free survival.